Tier 4 — mechanistic

Bioavailability of quercetin: problems and promises

X Cai, Z Fang, J Dou, A Yu, G Zhai
Current medicinal chemistry 2013 20(20):2572

Bibliography

PubMed
PMID 23514412
DOI
10.2174/09298673113209990120
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignNarrative review of quercetin delivery approaches
ModelNarrative or mixed evidence review
SampleFormulation and pharmacokinetic literature; no new clinical cohort
InterventionInclusion complexes, liposomes, nanoparticles, and micelles
DurationLiterature available at publication
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2013, this source examined forms, absorption and food sources. Its evidence base was Formulation and pharmacokinetic literature; no new clinical cohort. It evaluated Inclusion complexes, liposomes, nanoparticles, and micelles across Literature available at publication.

Experimental delivery systems could improve solubility and measured exposure.

Promising delivery does not establish clinical benefit, product equivalence, or safety of every formulation. Many approaches were experimental.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Experimental delivery systems could improve solubility and measured exposure.
  • The recorded outcome domains were Exposure and pharmacokinetics.

What this study can and cannot tell us

  • Promising delivery does not establish clinical benefit, product equivalence, or safety of every formulation. Many approaches were experimental.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 4
A critical examination of human data for the biological activity of quercetin and its phase-2 conjugates
Gary Williamson et al. · Critical reviews in food science and nutrition · 2025
Tier 4
Enzymatically Modified Isoquercitrin: Production, Metabolism, Bioavailability, Toxicity, Pharmacology, and Related Molecular Mechanisms
Aleksandra Owczarek-Januszkiewicz et al. · International journal of molecular sciences · 2022
Tier 4
Recent advances on the improvement of quercetin bioavailability
Kevser Kandemir et al. · Trends in Food Science & Technology · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology